1-3 of 3
John Shin
Close
Sort by
Journal Articles

G-CSF/Plerixafor Dual-Mobilized Donor Derived CD33CAR T-Cells As Potent and Effective AML Therapy in Pre-Clinical Models

Giacomo Canesin, Hillary Hoyt, Reid Williams, Mariana Silva, Melissa Chng, Christopher Cummins, Matthew Ung, Huan Qiu, John Shin, Jianxin Hu, Gary Ge, Julian Scherer, Tirtha Chakraborty, Sadik Kassim
Journal: Blood
Blood (2021) 138 (Supplement 1): 1716.
https://doi.org/10.1182/blood-2021-153868
Published: 2021
Journal Articles

Actr Platform As an Adaptable, Universal T Cell Therapy That Can Target Multiple Tumor Antigens to Overcome Antigen Escape

Greg Motz, PhD, Eugene Choi, M.S., Tooba Cheema, PhD, Taylor Friedman, B.A., Taylor Hickman, B.S., Allison Nelson, B.S., John Shin, BSc, Ryan Boomer, B.A., James Hemphill, PhD, Kathleen McGinness, PhD, Heather A Huet, PhD, Seth A Ettenberg, PhD
Journal: Blood
Blood (2016) 128 (22): 3362.
https://doi.org/10.1182/blood.V128.22.3362.3362
Published: 2016
Journal Articles

Targeting CD20+ Relapsed Refractory B Cell Lymphoma with ACTR087, Antibody-Coupled T-Cell Receptor (ACTR) Engineered Autologous T Cells, in Combination with Rituximab

Heather A Huet, PhD, Casey Judge, M.S., R. Anthony Barnitz, PhD, Ryan Boomer, BSc, Kathleen McGinness, PhD, John Shin, BSc, Tooba Cheema, PhD, Kathleen Whiteman, M.S., Birgit Schultes, PhD, Ann Ranger, PhD, Lan Cao, PhD, Geoffrey Hodge, PhD, Michael J. Vasconcelles, MD, Seth A Ettenberg, PhD
Journal: Blood
Blood (2016) 128 (22): 3512.
https://doi.org/10.1182/blood.V128.22.3512.3512
Published: 2016